Table 2 Treatments under research and development for Lassa fever evaluated in small animal models

From: Baseline mapping of Lassa fever virology, epidemiology and vaccine research and development

Treatment

Efficacy [survival in %]

Animal model

Citation

Stampidine (Nucleoside analog)

a75% (25 mg/kg) and 90% (50 mg/kg)

CBA mice

141

Zidampidine (Nucleoside analog)

a25% (25 mg/kg)

CBA mice

142

Interferon-α (Interferon alfacon-1)

100% (10 mg/kg/d x 5 d); Synergistic effect with ribavirin to reduce mortality, FDA approved

Hamsters (Pichinde virus model)

143

Favipiravir (T-705)

100% (300 mg/kg/d x 15 d)

Guinea pigs, transgenic mice

48,116,144–146

Antibody therapy (Monoclonal)

b100% with a cocktail of five human monoclonals (30 mg/kg)

Guinea pigs

72

ST-193 (Small-molecule arenavirus entry inhibitor)

c62.5% (25 mg/kg and 80 mg/kg)

Guinea pigs

135,147

  1. aInitial Stampidine or Zidampidine dosages were delivered 24 (h) and 1 h prior to LASV inoculation, followed by subsequent dosages at 24, 48, 72, and 96 h post inoculation
  2. bAntibody cocktails were delivered at challenge (Day 0), followed by Days 3 and 6 post infection
  3. cST-193 was delivered 1 h prior to LASV inoculation, followed by daily treatments for a total of 14 doses
Back to article page